This research study demonstrating the feasibility of using molecular tumor markers as the basis for selecting the chemotherapeutic agents to use in patients with metastatic pancreatic cancer. Based on these promising results a larger phase II clinical trial; has been initiating using molecular bio markers to guide the choice of second line therapies.
In addition, the expression of excision repair cross complementation group 1 (ERCC1) and thymidylate synthase (TS) may be markers; for platinum resistance and 5FU resistance, respectively; study have recently performing a review of the value of these predictive biomarkers across disease types, and our findings suggest that there is value at a minimum to exploring the utilization of these biomarkers in clinical trials for patients with pancreatic and other cancer types.
Molecular Tumor Markers
However, present there is wide adoption of tumor molecular profiling; there is a dearth of evidence linking molecular bio markers for treatment selection to prediction of treatment outcomes in patients with metastatic pancreatic cancer. By designing a composite treatment algorithm based on three established predictive markers of response to chemotherapy.
Study testing the tumor biopsy samples for the presence of these markers and, based on the results; assigned the patients to treatment with two chemotherapeutic agents most likely to elicit a response.chemotherapy regimens in current clinical practice were evaluated empirically in nonbio marker enriched patient populations; and there are no accompanying predictive tools to guide their use in patients.
But in some availability of molecular profiling, there is scarcity of high quality prospective data evaluating the efficacy of linking molecular profiles; to specific treatment choices in patients with pancreatic adenocarcinoma. But some studies have exploring the predictive role of some biomarkers to specific chemotherapeutic agents. One such biomarker is ribonucleotide reductase catalytic subunit M1 (RRM1) expression; which is a potential marker for gemcitabine resistance.
But by some dose modifications for adverse events were detailed in the protocol for each regimen. Treatment in the assigning subgroup was continuing until disease progression or patient intolerance occurred; and all patients were following until death.By this researchers reporting the promising progression free survival and overall survival; with a partial response seen in 28% of patients and stable disease in 50% on completion of the study.